Indoco Remedies Limited (INDOCO.BO)
INR 337.6
(-0.35%)
INR 337.6
(-0.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.64 Billion INR | -15.3% |
| 2022 | 2.88 Billion INR | -12.51% |
| 2021 | 3.24 Billion INR | 36.64% |
| 2020 | 2.27 Billion INR | 81.78% |
| 2019 | 1.2 Billion INR | 61.64% |
| 2018 | 822.43 Million INR | -40.92% |
| 2017 | 1.34 Billion INR | -17.82% |
| 2016 | 1.69 Billion INR | -1.49% |
| 2015 | 1.71 Billion INR | 2.9% |
| 2014 | 1.65 Billion INR | 48.09% |
| 2013 | 1.21 Billion INR | 20.32% |
| 2012 | 936.45 Million INR | 9.77% |
| 2011 | 853.1 Million INR | 20.12% |
| 2010 | 705.61 Million INR | 22.17% |
| 2009 | 582.21 Million INR | -23.89% |
| 2008 | 763.78 Million INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 623.17 Million INR | 2.12% |
| 2005 | 610.21 Million INR | 24.33% |
| 2004 | 490.81 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 477.7 Million INR | -31.52% |
| 2024 Q2 | 129.89 Million INR | -14.32% |
| 2023 Q2 | 758 Million INR | 15.58% |
| 2023 Q1 | 655.8 Million INR | 0.51% |
| 2023 FY | - INR | -15.3% |
| 2023 Q4 | 488.7 Million INR | -25.1% |
| 2023 Q3 | 652.5 Million INR | -13.92% |
| 2022 FY | - INR | -12.51% |
| 2022 Q1 | 725.8 Million INR | -10.84% |
| 2022 Q2 | 882 Million INR | 21.52% |
| 2022 Q3 | 624 Million INR | -29.25% |
| 2022 Q4 | 652.5 Million INR | 4.57% |
| 2021 Q2 | 874.5 Million INR | -0.35% |
| 2021 Q1 | 877.6 Million INR | 58.2% |
| 2021 FY | - INR | 36.64% |
| 2021 Q3 | 736.1 Million INR | -15.83% |
| 2021 Q4 | 814.08 Million INR | 10.59% |
| 2020 FY | - INR | 81.78% |
| 2020 Q1 | 489.1 Million INR | 81.4% |
| 2020 Q4 | 554.73 Million INR | -8.37% |
| 2020 Q3 | 605.4 Million INR | -1.14% |
| 2020 Q2 | 612.4 Million INR | 25.21% |
| 2019 FY | - INR | 61.64% |
| 2019 Q3 | 355.9 Million INR | 7.17% |
| 2019 Q1 | 230.5 Million INR | -29.64% |
| 2019 Q4 | 269.63 Million INR | -24.24% |
| 2019 Q2 | 332.1 Million INR | 44.08% |
| 2018 Q3 | 252.8 Million INR | 102.73% |
| 2018 Q1 | 117.2 Million INR | 0.0% |
| 2018 FY | - INR | -40.92% |
| 2018 Q4 | 327.58 Million INR | 29.58% |
| 2018 Q2 | 124.7 Million INR | 6.4% |
| 2017 FY | - INR | -17.82% |
| 2016 FY | - INR | -1.49% |
| 2015 FY | - INR | 2.9% |
| 2014 Q1 | 371.9 Million INR | 0.0% |
| 2014 FY | - INR | 48.09% |
| 2013 Q1 | 245.4 Million INR | -0.52% |
| 2013 FY | - INR | 20.32% |
| 2012 Q4 | 246.67 Million INR | 0.0% |
| 2012 FY | - INR | 9.77% |
| 2011 FY | - INR | 20.12% |
| 2010 FY | - INR | 22.17% |
| 2009 FY | - INR | -23.89% |
| 2008 FY | - INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | - INR | 2.12% |
| 2005 FY | - INR | 24.33% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 78.934% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -287.825% |
| Sigachi Industries Limited | 883.39 Million INR | -199.645% |
| Bal Pharma Limited | 345.59 Million INR | -665.948% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 61.422% |
| Medico Remedies Limited | 150.37 Million INR | -1660.267% |
| Lasa Supergenerics Limited | -65.08 Million INR | 4167.385% |
| Venus Remedies Limited | 711.8 Million INR | -271.881% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 170.942% |
| Alpa Laboratories Limited | 86.12 Million INR | -2973.431% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -69.272% |
| Shilpa Medicare Limited | 2.58 Billion INR | -2.283% |
| Aarti Drugs Limited | 3.24 Billion INR | 18.518% |
| Lupin Limited | 36.96 Billion INR | 92.84% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 95.716% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 95.292% |
| Windlas Biotech Limited | 781.72 Million INR | -238.619% |
| Suven Life Sciences Limited | -992.78 Million INR | 366.63% |
| Eris Lifesciences Limited | 6.98 Billion INR | 62.112% |
| Valiant Laboratories Limited | 12.73 Million INR | -20679.135% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 71.643% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 193.804% |
| Ipca Laboratories Limited | 13.29 Billion INR | 80.097% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -78.972% |
| Achyut Healthcare Limited | 524 Thousand INR | -505062.977% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.087% |
| Bajaj HealthCare Limited | 444.51 Million INR | -495.491% |
| RPG Life Sciences Limited | 1.28 Billion INR | -106.559% |
| Mankind Pharma Limited | 28.09 Billion INR | 90.578% |
| Laurus Labs Limited | 8 Billion INR | 66.937% |
| Piramal Pharma Limited | 13.05 Billion INR | 79.724% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -515.199% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 92.439% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 72.474% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 76.665% |
| Unichem Laboratories Limited | 742.35 Million INR | -256.575% |
| Sequent Scientific Limited | 549.8 Million INR | -381.458% |
| Novartis India Limited | 1.26 Billion INR | -108.544% |
| Wanbury Limited | 985.49 Million INR | -168.603% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 43.405% |
| Wockhardt Limited | 1.08 Billion INR | -145.098% |
| Themis Medicare Limited | 562.6 Million INR | -370.498% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -718.356% |
| Jubilant Pharmova Limited | 8 Billion INR | 66.937% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 61.429% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 97.001% |
| Divi's Laboratories Limited | 25.43 Billion INR | 89.591% |
| NATCO Pharma Limited | 18.79 Billion INR | 85.916% |
| Gufic Biosciences Limited | 1.48 Billion INR | -78.796% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -1.552% |
| Ind-Swift Limited | 1.06 Billion INR | -148.534% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 12.186% |
| FDC Limited | 4.4 Billion INR | 39.863% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 3299.746% |
| Granules India Limited | 8.6 Billion INR | 69.234% |
| Medicamen Biotech Limited | 245.66 Million INR | -977.527% |
| Alkem Laboratories Limited | 24.19 Billion INR | 89.06% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -12.316% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -20165.304% |
| Brooks Laboratories Limited | 41.72 Million INR | -6243.592% |
| Megasoft Limited | 284.73 Million INR | -829.668% |
| ZIM Laboratories Limited | 462.09 Million INR | -472.835% |
| Strides Pharma Science Limited | 3.76 Billion INR | 29.687% |
| Neuland Laboratories Limited | 4.74 Billion INR | 44.251% |
| Morepen Laboratories Limited | 1.72 Billion INR | -53.368% |
| Hikal Limited | 2.69 Billion INR | 1.678% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 32.29% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -820.955% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1413.069% |
| Hester Biosciences Limited | 539.47 Million INR | -390.677% |